Delve deep into the world of RET+ NSCLC with Dr. Maya Khalil, a distinguished Hematology-Oncologist from the Kirklin Clinic of UAB Hospital and an Assistant Professor at the University of Alabama at Birmingham. In this revealing segment from the 2022 Targeted Therapies Forum, Dr. Khalil offers an illuminating case study of a patient she treated, shedding light on the intricacies of RET+ NSCLC and the complexities of gene alterations.
We extend our gratitude to our esteemed sponsors: #Novartis, #Janssen, #Blueprintmedicine, #TakedaOncology, #Astrazeneca, #LillyOncology, and #genentech for their unwavering support.
Eager to dive deeper into oncology’s evolving landscape? Make your way to http://cancerGRACE.org/. Engage with top-tier experts and partake in enriching conversations at https://cancergrace.org/forum.